Introduction
Glucagon-like peptide-1 (GLP-1) receptor agonists have become a cornerstone in the management of type 2 diabetes and obesity. These medications, including semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and others, offer significant benefits in glycemic control and weight loss. However, as their use becomes more widespread, a growing number of patients report experiencing fatigue—a symptom that can be debilitating and, in some cases, overlooked in clinical practice.
This article explores the phenomenon of fatigue associated with GLP-1 receptor agonists, its potential mechanisms, and strategies for healthcare providers and patients to manage this emerging side effect.
What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists mimic the action of the endogenous incretin hormone GLP-1. They stimulate insulin secretion in response to meals, suppress glucagon release, slow gastric emptying, and promote satiety. These effects lead to improved blood glucose control and significant weight loss. Their benefits have also extended to cardiovascular risk reduction, making them a popular option for many patients with metabolic syndrome.
Emerging Concern: Fatigue and GLP-1 Agonists
Fatigue is not listed as a common or serious adverse effect in the product labels of GLP-1 medications. However, real-world patient experiences and some observational reports suggest that fatigue—both physical and mental—can occur with the initiation or continued use of these drugs. The symptom may be transient or persistent, and it can significantly impact a patient’s quality of life and adherence to therapy.
Possible Mechanisms Behind GLP-1-Induced Fatigue
Who Is Most at Risk?
Conclusion
While GLP-1 receptor agonists offer transformative benefits for many patients, fatigue is an emerging and potentially under-recognized side effect. Understanding the underlying mechanisms and implementing thoughtful clinical strategies can help patients maximize the benefits of therapy while minimizing the burden of fatigue. Further research is needed to better define the prevalence, pathophysiology, and optimal management of GLP-1-associated fatigue.
References